Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial

被引：0
|
作者：
Dodick, D. [1 ]
Nahas, S. [2 ]
Pozo-Rosich, P. [3 ,4 ]
Bilchik, T. [5 ]
McAllister, P. [6 ]
Finnegan, M. [7 ]
Ma, J. [7 ]
Chalermpalanupap, T. [7 ]
Dabruzzo, B. [7 ]
Lipton, R. [8 ]
机构：
[1] Mayo Clin, Scottsdale, AZ USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Autonomous Univ Barcelona, Barcelona, Spain
[5] Yale Sch Med, New Haven, CT USA
[6] New England Inst Neurol & Headache, Stamford, CT USA
[7] AbbVie, Madison, NJ USA
[8] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2022年 / 23卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P110
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Sustained response of galcanezumab in migraine prevention: Patient--level data from a post hoc analysis in patients with episodic or chronic migraine
    Tepper, Stewart J.
    Dong, Yan
    Vincent, Maurice
    Wietecha, Linda A.
    HEADACHE, 2023, 63 (10): : 1380 - 1390
  • [32] Effect of atogepant on the Activity Impairment in Migraine-Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
    Lipton, R.
    Pozo-Rosich, P.
    Dodick, D.
    Friedman, D. I.
    Ailani, J.
    Smith, J.
    Stokes, J.
    Schwefel, B.
    Gandhi, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [33] Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial
    Kim, Byung-Kun
    Cho, Soo-Jin
    Han, Jeong Hee
    Dell'Agnello, Grazia
    Panni, Tommaso
    Kim, Manho
    Oh, Kyungmi
    Moon, Heui-Soo
    Chu, Min Kyung
    JOURNAL OF CLINICAL NEUROLOGY, 2023, 19 (05): : 483 - 494
  • [34] Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
    Klein, Brad C.
    Miceli, Rosa
    Severt, Lawrence
    McAllister, Peter
    Mechtler, Laszlo
    McVige, Jennifer
    Diamond, Merle
    Marmura, Michael J.
    Guo, Hua
    Finnegan, Michelle
    Trugman, Joel M.
    CEPHALALGIA, 2023, 43 (01)
  • [35] Impact of atogepant on migraine day reduction, response rate, and patient-reported outcomes in participants with episodic migraine and comorbid depressive symptoms: subgroup analysis from the ELEVATE trial
    Vernieri, F.
    Gandhi, P.
    Ashina, M.
    Seng, E.
    Lipton, R. B.
    Nagy, K.
    Liu, Y.
    Carr, K.
    Stokes, J.
    Pozo-Rosich, P.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [36] Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
    Mamoru Shibata
    Atsuko Nihira
    Yuka Tanji
    Akichika Ozeki
    Hideyuki Imagawa
    Mika Komori
    Neurology and Therapy, 2023, 12 : 2007 - 2019
  • [37] Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
    Shibata, Mamoru
    Nihira, Atsuko
    Tanji, Yuka
    Ozeki, Akichika
    Imagawa, Hideyuki
    Komori, Mika
    NEUROLOGY AND THERAPY, 2023, 12 (06) : 2007 - 2019
  • [38] SOCIAL AND FUNCTIONAL OUTCOMES: RESULTS: FROM A 12-WEEK PHASE 3 STUDY OF 2 DOSES ARIPIPRAZOLE LAUROXIL VS PLACEBO: A POST HOC ANALYSIS
    Stanford, Arielle
    Risinger, Robert
    Claxton, Amy
    Liu, ChihChin
    Du, Yangchun
    Jamal, Hassan
    Weiden, Peter
    SCHIZOPHRENIA BULLETIN, 2017, 43 : S218 - S218
  • [39] Reversion From Chronic to Episodic Migraine and Effects on Patient-reported Outcomes Following Treatment With Erenumab: Post-hoc Analysis of the Randomised, 12-week, Double-blind DRAGON Study
    Wang, Shuu-Jiun
    Kim, Byung-Kun
    Wang, Hebo
    Zhou, Jiying
    Wan, Qi
    Yu, Tingmin
    Lian, Yajun
    Arkuszewski, Michal
    Ecochard, Laurent
    Wen, Shihua
    Yin, Fangfang
    Li, Zheng
    Su, Wendy
    Yu, Shengyuan
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 29 - 31
  • [40] Atogepant Improved Patient- Reported Outcome (PRO) Measures of Activity Impairment in Migraine-Diary and Headache Impact Test in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, Richard B.
    Pozo-Rosich, Patricia
    Blumenfeld, Andrew M.
    Li, Ye
    Severt, Lawrence
    Stokes, Jonathan
    Gandhi, Pranav
    Dodick, David W.
    NEUROLOGY, 2021, 96 (15)
12345